141 related articles for article (PubMed ID: 18700563)
1. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
2. The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.
Sasamura H; Nakaya H; Julius S; Takebayashi T; Sato Y; Uno H; Takeuchi M; Ishiguro K; Murakami M; Ryuzaki M; Itoh H;
Hypertens Res; 2008 Oct; 31(10):1843-9. PubMed ID: 19015590
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Mann J
Internist (Berl); 2007 Apr; 48(4):436-8. PubMed ID: 17342351
[No Abstract] [Full Text] [Related]
4. From TROPHY with pride.
Julius S; Schork A; Egan BM
Am J Hypertens; 2007 Mar; 20(3):342-3; author reply 343-5. PubMed ID: 17324750
[No Abstract] [Full Text] [Related]
5. Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
Staessen JA; Richart T; Birkenhäger WH
Eur Heart J; 2009 May; 30(10):1164-6. PubMed ID: 19363059
[No Abstract] [Full Text] [Related]
6. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on prehypertension.
Nesbitt SD
J Cardiometab Syndr; 2006; 1(5):364-5. PubMed ID: 17679784
[TBL] [Abstract][Full Text] [Related]
8. Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B; Page SR
Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.
Turner MJ; van Schalkwyk JM
Am J Hypertens; 2008 Jan; 21(1):85-91. PubMed ID: 18091749
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of Cardiovascular Complications in Patients With Arterial Hypertension While Use of Angiotensin II Receptor Antagonists. Possibilities of Candesartan].
Savina NM
Kardiologiia; 2016 Jun; 56(6):63-67. PubMed ID: 28290850
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
14. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
[TBL] [Abstract][Full Text] [Related]
15. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan.
Suzuki H; Araki R
Drugs Today (Barc); 2010 Jun; 46(6):427-31. PubMed ID: 20571611
[TBL] [Abstract][Full Text] [Related]
17. Treating prehypertension.
Grassi DG
N Engl J Med; 2006 Jul; 355(4):416; author reply 417-8. PubMed ID: 16870923
[No Abstract] [Full Text] [Related]
18. Trial of preventing hypertension: design and 2-year progress report.
Julius S; Nesbitt S; Egan B; Kaciroti N; Schork MA; Grozinski M; Michelson E;
Hypertension; 2004 Aug; 44(2):146-51. PubMed ID: 15238567
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
García Donaire JA; Ruilope LM
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S22-30. PubMed ID: 17339065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
